Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1696

Sort by

Sort Order Select

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Wolfgang Kern, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4657.

https://doi.org/10.1182/blood-2019-130304

Published: 2019

Journal Articles

Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA

Ian Duncan, Natalie Danziger, Daniel Duncan, MD, Amanda Hemmerich, MD, Claire Edgerly, MD, Richard Huang, MD, Jo-Anne Vergilio, MD, Julia A Elvin, MD PhD, Jie He, PhD, Nicholas Britt, Prasanth Reddy, MD, Pratheesh Sathyan, MD, Brian Alexander, MD, Jeffrey S. Ross, MD, Charlotte Brown, PhD, Shakti H. Ramkissoon, MD PhD, Eric A. Severson, MD, PhD, MMSc

Blood (2019) 134 (Supplement_1): 4659.

https://doi.org/10.1182/blood-2019-131362

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Blood (2019) 134 (Supplement_1): 729.

https://doi.org/10.1182/blood-2019-122784

Published: 2019

Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Blood (2019) 134 (Supplement_1): 735.

https://doi.org/10.1182/blood-2019-122779

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, PhD, Allison Kaeding, MD, Christoph Schatz, PhD, Anette Sommer, PhD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 1370.

https://doi.org/10.1182/blood-2019-123794

Published: 2019

Journal Articles

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, MD, Fernando Martín Moro, Adolfo Saez-Martin, MD, Alejandro Luna, MD, Irene Garcia-Garcia, Berta Mercedes Michael Fernández, Jesus Villarrubia, PhD, Miguel Piris-Villaespesa, MD, Ernesto Roldan Santiago, Eulalia Rodríguez Martín, Gemma Moreno, MD, Valentín García Gutiérrez, PhD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2019) 134 (Supplement_1): 1433.

https://doi.org/10.1182/blood-2019-130190

Published: 2019

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

Rasoul Pourebrahimabadi, MD PhD, Zoe Alaniz, Lauren B Ostermann, Hung Alex Luong, Rafael Heinz Montoya, Peter P. Ruvolo, PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 523.

https://doi.org/10.1182/blood-2019-127245

Published: 2019

Journal Articles

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Ryosaku Inagaki, MSc, Masahiro Marshall Nakagawa, MD PhD, Yasuhito Nannya, MD PhD, Qi Xingxing, PhD, Lanying Zhao, MD, PhD, June Takeda, MD, Akinori Yoda, PhD, Ayana Kon, MD PhD, Hisashi Tsurumi, MD PhD, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 542.

https://doi.org/10.1182/blood-2019-126444

Published: 2019

Journal Articles

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

Stephanie C. Heidemann, MD, Brian Bursic, Sasan Zandi, MD PhD, Hongbing Li, PhD, Robert J Klaassen, MD FRCPC, Sharon Abish, MD, Meera Rayar, Vicky R. Breakey, BSc,MDFRCPC, Houtan Moshiri, PhD, Santhosh Dhanraj, PhD, Richard de Borja, PhD, Adam Shlien, PhD, John E. Dick, PhD, Yigal Dror, MDFRCPC, Sagi Abelson, PhD

Blood (2019) 134 (Supplement_1): 1223.

https://doi.org/10.1182/blood-2019-130534

Published: 2019

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

Frequency and Prognostic Impact of IKZF1 and Co-Existed Gene Alterations in Childhood B-ALL in Taiwan

Hsi-Che Liu, MD, Ying-Jung Huang, PhD, Ting-Chi Yeh, MD, Tang-Her Jaing, MD, Chao-Ping Yang, MD, Shih-Hsiang Chen, MD, Jen-Yin Hou, MD, Tung-Huei Lin, MS, Iou-Jih Hung, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 2750.

https://doi.org/10.1182/blood-2019-128863

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Blood (2019) 134 (Supplement_1): 2751.

https://doi.org/10.1182/blood-2019-125713

Published: 2019

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

NARROW

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Frequency and Prognostic Impact of IKZF1 and Co-Existed Gene Alterations in Childhood B-ALL in Taiwan

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only